Pancreas Cancer Specialized Program of Research Excelle*

Excelle 胰腺癌专门研究计划*

• 批准号: 7247994
• 负责人: Anton Wellstein
• 金额: $ 20.97万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-30 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7247994
• 关键词: Address; Apoptosis; Basic Science; Biology; Caring; Cell Communication; Cells; Clinical; Clinical Research; Clinical Treatment; Collaborations; Databases; Detection; Development; Diagnosis; Disease; Early Diagnosis; Endothelium; Excision; Funding; German population; Goals; Growth Factor; Health system; Healthcare Systems; Heparin Binding Growth Factor; Hospitals; Institution; Knowledge; Life; Liquid substance; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of pancreas; Methods; Mitogen-Activated Protein Kinases; Modeling; Molecular; Molecular Target; NCOA3 gene; Neoplasm Metastasis; Nerve Block; Neuregulins; Neurons; Nuclear Receptors; Pancreas; Pathway interactions; Patient Outcomes Assessments; Patients; Phase I Clinical Trials; Radiation; Reproduction spores; Research; Research Infrastructure; Research Institute; Research Personnel; Resources; Role; Serum; Signal Transduction; Specialized Program of Research Excellence; System; Tissues; Translating; Translational Research; Tumor Bank; Universities; cancer cell; career; design; inhibitor/antagonist; killings; neoplastic cell; novel; novel strategies; pancreatic neoplasm; pleiotrophin; programs

The goal of this Specialized Program of Research Excellence (SPORE) in pancreas cancer is to translate outstanding hypothesis-driven basic research into clinical treatment that saves lives. Pancreatic cancer is a devastating cancer that kills patients not just because it may be extremely aggressive but also because it is diagnosed late. This SPORE is a unique collaboration between Georgetown University, Geisinger Health System and INDIVUMED a German Research Institute with a German hospital consortium that brings together an outstanding academic institution, a large regional healthcare system and a German basic and clinical research system to address the biology of pancreatic cancer and clinical care. Project 1 focuses on inhibition of pleiotrophin, a novel heparin-binding growth factor that promotes invasion and metastasis in pancreatic cancer. Project 2 focuses on the role of neuregulins and pleiotrophin in an established model of neuron:tumor cell interaction with the goal of developing methods to block neural invasion by malignant pancreas cells that may ultimately aid in disease palliation. Project 3 focuses on recent findings that inhibition of the nuclear receptor coactivator AIB1 within pancreas cancer cells and adjacent endothelium may block signaling from multiple growth factors to enhance apoptosis. The activation of the ras/MAP kinase pathway that occurs in up to 90% of pancreas cancer is the focus for novel approaches to radiation sensitization in Proiect 4. Investigators at Georgetown have developed a rafl antisense inhibitor that is already in Phase I trial and have developed other molecular targets in the pathway that are complementary. In addition, this SPORE is developing the infrastructure and resources to acquire tissues and bodily fluids from patients (Pancreatic Tumor Bank and Serum Detection & Molecular Identification Cores) with an expected 120 curative resections a year. The SPORE will utilize a biostatistical core to insure that all projects have appropriate designs, methods of analysis, and an integrated database for reporting patient outcomes. Further, the SPORE will support developmental projects designed to generate new knowledge and approaches to early detection and promote the development of career tracks dedicated to translational research in pancreatic cancer. This SPORE is also establishing interactions with SPOREs in other institutions as well as with other NCI- and NIH-funded programs to promote the aggressive development of novel therapies for the control of pancreas cancer

这个卓越研究的专业计划（SPORE）在胰腺癌的目标是翻译 杰出的假设驱动的临床治疗基础研究，挽救生命。胰腺癌是一 毁灭性的癌症杀死病人，不仅因为它可能是非常积极的，而且因为它是 诊断晚了这个孢子是乔治敦大学，盖辛格健康之间的独特合作 系统和个人德国研究所与德国医院财团，带来 一个优秀的学术机构，一个大型的区域医疗保健系统和一个德国的基本和 临床研究系统，以解决胰腺癌的生物学和临床护理。项目1的重点是 抑制多效生长因子，一种新的肝素结合生长因子，促进肿瘤细胞的侵袭和转移， 胰腺癌项目2的重点是神经调节素和多效因子在一个已建立的模型中的作用， 神经元：肿瘤细胞相互作用，目的是开发阻断恶性肿瘤侵袭神经的方法。 胰腺细胞可能最终有助于缓解疾病。项目3的重点是最近的调查结果， 抑制胰腺癌细胞和邻近内皮细胞内的核受体辅激活剂AIB 1 可以阻断来自多种生长因子的信号传导以增强凋亡。ras/MAP激酶的激活 在90%的胰腺癌中发生的这一途径是放射治疗新方法的焦点 项目4中的致敏作用。乔治敦大学的研究人员已经开发出一种rafl反义抑制剂， 已经在I期试验中，并且已经开发了互补途径中的其他分子靶点。 此外，该SPORE正在开发获取组织和体液的基础设施和资源 来自具有以下特征的患者（胰腺肿瘤库和血清检测和分子鉴定核心）： 预计每年有120例根治性切除SPORE将利用生物统计学核心来确保所有 项目具有适当的设计、分析方法和用于报告患者的综合数据库 结果。此外，SPORE将支持旨在产生新知识的发展项目 和方法，以早期发现和促进职业轨道的发展，专门用于翻译 胰腺癌的研究此SPORE还与其他SPORE建立交互 机构以及其他NCI和NIH资助的计划，以促进积极发展， 控制胰腺癌的新疗法